Linda Marbán

Linda Marban serves as the Chief Executive Officer of Capricor Therapeutics, Inc., a biotechnology company dedicated to developing cell and exosome-based therapeutics for various diseases. Since joining Capricor in September 2010, Linda has overseen significant advancements, including the upcoming presentation of final data from the Phase II HOPE-2 clinical trial for CAP-1002, targeting boys and young men with late-stage Duchenne muscular dystrophy. Prior to this role, Linda held the position of Vice President of Business Development at Excigen, Inc.